These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 10255154)
1. Competition of high-priced new drugs holds down prices of older drugs. Hosp Purch Manage; 1982 May; 7(5):14-5. PubMed ID: 10255154 [No Abstract] [Full Text] [Related]
2. Drug Price Index declines as prices weaken for older drugs. Hosp Mater Manage; 1986 May; 11(5):21-2. PubMed ID: 10277138 [No Abstract] [Full Text] [Related]
3. Biotech drugs: high costs becoming hard to swallow. Wagner M Mod Healthc; 1992 Jan; 22(2):24-5, 28-9. PubMed ID: 10115803 [TBL] [Abstract][Full Text] [Related]
6. Hospital pharmacy and industry--conflict and collaboration. Gouveia WA Am J Hosp Pharm; 1984 Jul; 41(7):1391-4. PubMed ID: 6465157 [No Abstract] [Full Text] [Related]
7. Biotechnology drugs create new maze of concerns for hospitals. Lumsdon K Hospitals; 1991 Dec; 65(23):32, 34-5. PubMed ID: 1937456 [TBL] [Abstract][Full Text] [Related]
8. Which bottom line? Shane R Am J Hosp Pharm; 1991 Oct; 48(10):2130. PubMed ID: 1781465 [No Abstract] [Full Text] [Related]
9. Appraisal of drug costs to hospitals. Salman L J Hosp Dent Pract; 1979; 13(1):5-9. PubMed ID: 296180 [No Abstract] [Full Text] [Related]
10. Hospitals hit with higher drug costs. Wagner M Mod Healthc; 1991 Mar; 21(10):16. PubMed ID: 10109612 [No Abstract] [Full Text] [Related]
11. Marketplace. How drug company mergers affect HMOs and hospitals. Moskowitz DB Faulkner Grays Med Health; 1997 Jun; 51(23):suppl 2 p.. PubMed ID: 10167794 [No Abstract] [Full Text] [Related]
12. Shades of gray. Secondary drug distributors raise questions. Lee J Mod Healthc; 2011 Oct; 41(41):10, 12. PubMed ID: 22111494 [No Abstract] [Full Text] [Related]
13. Competition is driving down prices of many high-volume pharmaceuticals. Kuntz EF Mod Healthc; 1983 Dec; 13(12):60-2. PubMed ID: 10264040 [No Abstract] [Full Text] [Related]
14. HMM drug price index advances at 4% annual rate. Hosp Mater Manage; 1987 Nov; 12(11):14-5. PubMed ID: 10285402 [No Abstract] [Full Text] [Related]
15. A commentary on high-cost drugs. de Leon RF Curr Concepts Hosp Pharm Manage; 1989; 11(3):4-7. PubMed ID: 10318277 [TBL] [Abstract][Full Text] [Related]
16. Generic prices expected to fall 3%. Matei D Hosp Mater Manage; 1990 Feb; 15(2):1, 8-10. PubMed ID: 10103550 [No Abstract] [Full Text] [Related]
17. Generic drug prices fall 7%-24%; groups sort out manufacturers. Bernstein T Hosp Mater Manage; 1989 Feb; 14(2):8-10. PubMed ID: 10318186 [No Abstract] [Full Text] [Related]
18. Drug price inflation slows but competition is limited. Hosp Purch Manage; 1983 Aug; 8(8):13-4. PubMed ID: 10261667 [No Abstract] [Full Text] [Related]
19. Reform calls for new relationships. Black RC Healthc Exec; 1993; 8(3):25. PubMed ID: 10125603 [TBL] [Abstract][Full Text] [Related]
20. Drugmakers fight for good name. Stakes high, challenges many for providers who seek generic products. Becker C Mod Healthc; 2001 Aug; 31(35):28-33, 1. PubMed ID: 11550428 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]